The reiteration of a Perform rating by Oppenheimer's analyst suggests that there are no significant short-term changes expected in the performance of Elicio Therapeutics' stock. This indicates a neutral impact on the stock price in the short term, as the market's expectations are likely already aligned with the analyst's outlook.